{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-090064","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-08-04T11:20:18+00:00","discovered_at":"2026-08-04T11:25:04.478804+00:00","generated_at":"2026-08-04T11:25:09.739079+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Theriva Biologics shareholders approve 2M share increase in stock plan, reelect directors at 2026 annual meeting","bullets":["Shareholders approved Amendment No. 4 to 2020 Stock Incentive Plan, increasing shares from 4.5M to 6.5M.","All four director nominees elected: Kraws, Shallcross, Monahan, Wolf.","Ratified BDO USA as independent auditor for FY2026.","Approved charter amendment to increase authorized shares; Board has discretion to file.","Approved issuance of common stock upon exercise of outstanding warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-090064","json":"https://secwatch.observer/filing/0001104659-26-090064.json","markdown":"https://secwatch.observer/filing/0001104659-26-090064.md","text":"https://secwatch.observer/filing/0001104659-26-090064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/0001104659-26-090064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926090064/tm2619846d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:25:09.739079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}